In vitro and in vivo antitumor efficacy of CLA-PTX on B16-F10 melanoma cells

doi:10.5246/jcps.2014.01.007

Abstract

Abstract:

The purpose of this study was to investigate the potential antitumor efficacy of conjugated linoleic acid-paclitaxel (CLA-PTX) on B16-F10 melanoma cell line in vitro and in vivo. The in vitro cytotoxicity, apoptosis and cell cycle of CLA-PTX were investigated. The in vitro cellular uptake of CLA-PTX in B16-F10 cells was also analyzed. The antitumor activity of CLA-PTX was also evaluated in B16-F10 tumor-bearing C57BL6/N mice in vivo. The in vitro cytotoxicity results showed that the IC₅₀ of the CLA-PTX is (4.25±0.43) µM, compared with that of (6.70±0.80) µM in PTX treatment group (P<0.01). CLA-PTX increased the percentage of total apoptotic cells compared with that of control and PTX treatment groups (P<0.01). Compared with untreated cells, CLA-PTX arrested cell cycle progression at the S phase, whereas PTX caused accumulation of cell at G₂-M phase both along with the reduction of the cellular fraction arrested at the G₁ phase. The amount of cellular uptake of CLA-PTX was significantly higher than that of PTX (P<0.01). The in vivo antitumor activity of CLA-PTX was significantly higher than that of control and PTX treatment groups (P<0.01 or P<0.05). In conclusion, our study demonstrated that CLA-PTX has significant antitumor activity in B16-F10 cell line.

Key words: CLA-PTX, Apoptosis, Cell cycle, Cellular uptake, Antitumor efficacy

CLC Number:

R943

Supporting:

Jiesi Li, KeYang, Xiyu Ke, Ruo Du, Xuan Zhang*, Qiang Zhang. In vitro and in vivo antitumor efficacy of CLA-PTX on B16-F10 melanoma cells [J]. Journal of Chinese Pharmaceutical Sciences, 2014, 23(1): 46-53.

References

[1] Bildstein, L.; Dubernet, C.; Couvreur, P. Adv. Drug Deliv. Rev. 2011, 63, 3–23.

[2] Kratz, F.; Müller, I.A.; Ryppa, C.; Warnecke, A. ChemMedChem. 2008, 3, 20–53.

[3] Lu, Y.H.; Gao, X.Q.; Wu, M.; Zhang-Negrerie, D.; Gao, Q. Mini Rev. Med. Chem. 2011, 11, 611–624.

[4] Mahato, R.; Tai, W.; Cheng, K. Adv. Drug Deliv. Rev. 2011, 63, 659–670.

[5] Breistøl, K.; Balzarini, J.; Sandvold, M.L.; Myhren, F.; Martinsen, M.; De Clercq, E.; Fodstad, O. Cancer Res. 1999, 59, 2944–2949.

[6] Pignata, S.; Amant, F.; Scambia, G.; Sorio, R.; Breda, E.; Rasch, W.; Hernes, K.; Pisano, C.; Leunen, K.; Lorusso, D.; Cannella, L.; Vergote, I. Cancer Chemother. Pharmacol. 2011, 68, 1347–1353.

[7] Beppu, F.; Hosokawa, M.; Tanaka, L.; Kohno, H.; Tanaka, T.; Miyashita, K. J. Nutr. Biochem. 2006, 17, 830–836.

[8] Cunningham, D.C.; Harrison, L.Y.; Shultz, T.D. Anticancer Res. 1997, 17, 197–203.

[9] Maggiora, M.; Bologna, M.; Cerù, M.P.; Possati, L.; Angelucci, A.; Cimini, A.; Miglietta, A.; Bozzo, F.; Margiotta, C.; Muzio, G.; Canuto, R.A. Int. J. Cancer. 2004, 20, 909–919.

[10] Ke, X.Y.; Zhao, B.J.; Zhao, X.; Wang, Y.; Huang, Y.; Chen, X.M.; Zhao, B.X.; Zhao, S.S.; Zhang, X.; Zhang, Q. Biomaterials. 2010, 31, 5855–5864.

[11] Li, D.; Yang, K.; Li, J.S.; Ke, X.Y.; Duan, Y.; Du, R.; Song, P.; Yu, K.F.; Ren, W.; Huang, D.; Li, X.H.; Hu, X.; Zhang, X.; Zhang, Q. Int. J. Nanomed. 2012, 7, 6105–6114.

[12] Petrella, T.; Verma, S.; Spithoff, K.; Quirt, I.; McCready, D. ClinOncol (R CollRadiol). 2012, 24, 413–423.

[13] Zheng, H.; Gao, L.; Feng, Y.; Yuan, L.; Zhao, H.; Cornelius, L.A. Cancer Res. 2009, 15, 449–457.

[14] Larkin, J.M.; Fisher, R.A.; Gore, M.E. ClinOncol (R CollRadiol). 2012, 24, 410–412.

[15] Eisen, T.; Ahmad, T.; Flaherty, K.T. Gore, M.; Kaye, S.; Marais, R.; Gibbens, I.; Hackett, S.; James, M.; Schuchter, L.M.; Nathanson, K.L.; Xia, C.; Simantov, R.; Schwartz, B. Br. J. Cancer. 2006, 95, 581–586.

[16] Yang, X.Y.; Li, Y.X.; Li, M.; Zhang, L.; Feng, L.X.; Zhang, N. Cancer Lett. 2013, 334, 338–345.

[17] Vichai, V.; Kirtikara, K. Nat. Protoc. 2006, 1, 1112–1116.

[18] Koukourakis, M.I.; Giatromanolaki, A.; Harris, A.L.; Sivridis, E. Cancer Res. 2007, 66, 632–637.

[19] Vaskivuo, T.E.; Tapanainen, J.S. Reprod. Biomed. Online. 2003, 6, 24–35.

[20] Alonso-Castro, A.J.; Ortiz-Sánchez, E.; García-Regalado, A.; Ruiz, G.; Núñez-Martínez, J.M.; González-Sánchez, I.; Quintanar-Jurado, V.; Morales-Sánchez, E.; Dominguez, F.; López-Toledo, G.; Cerbón, M.A.; García-Carrancá, A. J. Ethnopharmacol. 2013, 145, 476–489.

[21] Bossy-Wetzel, E.; Green, D.R. Methods Enzymol. 2000, 322, 15–18.

[22] Guasconi, L.; Serradell, M.C.; Masih, D.T. Vet Immunol-Immunopathol. 2012, 148, 359–363.

[23] Xi, G.; Hu, X.; Wu, B.; Jiang, H.; Young, CY.; Pang, Y.; Yuan, H. Cancer Lett. 2011, 307, 141–148.

[24] Foss, M.; Wilcox, B.W.; Alsop, G.B.; Zhang, D. PLoS One. 2008, 3, e1476.

[25] Wu, J.; Guan, M.; Wong, P.F.; Yu, H.; Dong, J.; Xu, J. Food Chem. Toxicol. 2012, 50, 3019–3024.

[26] Miglietta, A.; Bozzo, F.; Bocca, C.; Gabriel, L.; Trombetta, A.; Belotti, S. Cancer Lett. 2006, 234, 149–157.

[27] Majumder, B.; Wahle, K.W.; Moir, S.; Schofield, A.; Choe, S.N. FASEB J. 2002, 16, 1447–1449.

[28] Palombo, J.D.; Ganguly, A.; Bistrian, B.R.; Menard, M.P. Cancer Lett. 2002, 177, 163–172.

[29] Fay, D.S. Semin. Cell Dev. Biol. 2005, 16, 397–406.

[30] Pae, H.O.; Yoo, J.C.; Choi, B.M.; Kang, C.L.; Kim, J.D.; Chung, H.T. Immunopharmacol. Immunotoxicol. 1999, 21, 667–682.

[31] Kalechman, Y.; Longo, D.L.; Catane, R.; Shani, A.; Albeck, M.; Sredni, B. Int. J. Cancer. 2000, 86, 281–288.

[32] Sauer, L.A.; Blask, D.E.; Dauchy, R.T. J. Nutr. Biochem. 2007, 18, 637–649.